New treatments for erectile dysfunction


  • Jason Seewoodhary Department of Diabetes Mellitus and Endocrinology, Glan Clwyd Hospital, Rhyl, Denbighshire, UK
  • Stephen Phooi Yew Wong Department of Diabetes Mellitus and Endocrinology, Glan Clwyd Hospital, Rhyl, Denbighshire, UK



Erectile dysfunction (ED) is common in men with diabetes and is associated with microvascular disease, maladaptation to chronic illness, poor quality of life, and increased levels of diabetes-specific health distress. Traditionally, most diabetologists were poor at asking about ED and patients themselves are not always forthcoming with information, given the embarrassing nature of the disease. However, times are changing and the inclusion of screening for ED in Quality and Outcomes Framework and current general practice templates emphasises its current importance. Licensed treatments have been limited in their application towards the provision of symptomatic relief and are offset by adverse effects, intolerance, limited effectiveness and contraindications in the presence of co-existent cardiovascular disease. This review critically considers the utility of novel treatments for ED in diabetes that have been developed to overcome these barriers.


McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83.

Jamieson F, Chalmers J, Duncan C, et al. Erectile dysfunction in type 1 diabetic males. Br J Diabetes Vasc Dis 2008;8:232-34.

De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 2002;25:284-91.

Grant P, Lipscomb D. How often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening tool. Acta Diabetol 2009;46:285-90.

Eardley I. Pathophysiology of erectile dysfunction. Br J Diabetes Vasc Dis 2002;2:272-6.

Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IEFF): a state-of-the-science review. Int J Impotence Res 2002;14:226-44.

Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impotence Res 2005;17:307-19.

Kalsi J, Kell P. Update on the oral treatments for male erectile dysfunction. Eur Acad Dermatol Venereol 2004;18:267-74.

Porst H, Hell-Momeni K, Buttner H. Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using Tadalafil once-daily. Exp Opin Pharmacother 2012;13:1481-94.

Muse® alprostadil urethral suppository. US Summary of Product Characteristics (Meda Pharmaceuticals). Available at (accessed January 2015).

Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68:386-91.

Rooney M, Pfister W, Mahoney M, et al. Long-term multi-centre study of the safety and efficacy of topical Alprostadil cream in male patients with erectile dysfunction. J Sex Med 2009;6:520-34.

Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Exp Opin Pharmacother 2014;15:421-8.

Zhao C, Kim S, Yang D, et al. Efficacy and safety of Avanafil for treating erectile dysfunction: results of a multi-centre, randomised, double-blind, placebo-controlled trial. Br J Urol Int 2012;110:1801-06.

Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of Lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7:1928-36.

Du W, Li J, Fan N, et al. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male 2014;17:107-11.

Ding H, Du W, Wang H, et al. Efficacy and safety of Udenafil for erectile dysfunction: a meta-analysis of randomised controlled trials. Urology 2012;80:134-9.

Fraga-Silva RA, Montecucco F, Mach F, et al. Pathophysiological role of the renin-angiotensin system on erectile function. Eur J Clin Invest 2013;43:978-85.

Fraga-Silva RA, Costa-Fraga FP, Savergnini SQ, et al. An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med 2013;10:2430-42.

Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14:27-31.

Vardi Y, Gruenwald I, Gedalia U, et al. Evaluation of penile revascularisation for erectile dysfunction: a 10-year follow-up. Int J Impotence Res 2004;16:181-6.

Blute M, Hakimian P, Kashanian J, et al. Erectile dysfunction and testosterone deficiency. Front Horm Res 2009;37:108-22.

Hakim L, Van der Aa F, Bivalacqua TJ, et al. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol 2012;9:520-36.







Most read articles by the same author(s)